This research is Trending!
View all ESC 2026 trials
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
Key result
Catheter-directed thrombolysis reduces mortality, PE recurrence, or decompensation ~90% vs standard anticoagulation.
- RR 0.10
- 95% CI 0.02 to 0.44
- P<0.001
- n=558
Why the trial?
In intermediate-high-risk pulmonary embolism, anticoagulation alone leaves some patients to deteriorate while systemic thrombolysis causes major bleeding, and catheter-directed thrombolysis had not been proven in a randomised outcomes trial. Prague 26 addressed that gap.
Does conventional catheter-directed thrombolysis reduce the composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days in patients with acute intermediate-high-risk pulmonary embolism compared to standard anticoagulation alone?
Population
558 patients with acute intermediate-high-risk PE; median age 64, 41% women
Comparison
Catheter-directed thrombolysis vs standard anticoagulation alone
Design
Multicenter randomized trial (11 Czech centres)
Follow-up
7 days (primary endpoint)
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts see PRAGUE-26 as a strong signal favoring catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism, but most stop short of calling it an immediate mandate for routine practice.
The cardiology community views the result as promising evidence that catheter-directed thrombolysis can prevent early deterioration in intermediate-high-risk PE without increasing bleeding. However, experts note that intracranial hemorrhage signals and the need for broader validation temper enthusiasm for immediate routine adoption. The live question is whether this trial will be enough to shift guidelines toward earlier catheter-based intervention in this patient population.
Still unclear
Whether the intracranial bleeding events seen in the thrombolysis arm will weigh against guideline adoption despite the overall similar bleeding rates. Whether these results, generated at 11 Czech centres, will generalize broadly enough to support routine CDT in intermediate-high-risk PE worldwide.
Key expert perspectives
Promising results, but not yet a mandate for routine CDT
Asher highlights the reduction in the 7-day primary endpoint from 6.8% to 0.7% (NNT=17), driven mainly by preventing cardiorespiratory deterioration. He views the results as promising but explicitly states they do not yet justify routine catheter-directed thrombolysis.
Distilled from their postX post
CMC. Michael GibsonInterventional / Structural Cardiology · Beth Israel Deaconess Medical CenterResults readoutAug 31
CDT reduced the primary composite versus standard anticoagulation at 7 days
Gibson discussed the trial alongside the PRAGUE-26 investigators, noting that catheter-directed thrombolysis reduced the composite of all-cause mortality, PE recurrence, or cardiorespiratory decompensation or collapse at 7 days versus standard anticoagulation.
Distilled from their postX post
CDT with alteplase lowered the risk of death, recurrent PE, or decompensation
Gupta summarized that among patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation.
Distilled from their postX post
Implication
Supports catheter-directed thrombolysis in intermediate-high-risk PE; confirms early-event reduction versus anticoagulation alone in this RCT.
Key Points
- To assess whether catheter-directed thrombolysis improves early clinical outcomes compared with standard anticoagulation alone in acute intermediate-high-risk pulmonary embolism.
- Multicenter randomized trial (PRAGUE-26) conducted across 11 centers in the Czech Republic involving 558 patients (median age 64 years; 41% women) with acute intermediate-high-risk pulmonary embolism.
- Patients were randomized to receive either conventional catheter-directed thrombolysis or standard anticoagulation alone, with primary clinical outcomes tracked through seven days.
- Catheter-directed thrombolysis significantly reduced the 7-day composite primary endpoint of all-cause mortality, pulmonary embolism recurrence, or cardiorespiratory decompensation (0.7% vs 6.8%; RR 0.10, 95% CI 0.02 to 0.44; p<0.001).
- Seven-day bleeding rates were similar between catheter-directed thrombolysis and anticoagulation alone (4.6% vs 5.0%; p=0.846), with two intracranial hemorrhages in the thrombolysis arm versus none in standard care.
Evidence details
What drove the result?
| Outcome | CDT | Anticoag |
|---|---|---|
| Death, PE recurrence, or cardiorespiratory decompensation/collapse at 7 days | 0.7% | 6.8% |
| Primary composite · RR 0.10 (95% CI 0.02-0.44; p<0.001); driven mainly by less decompensation or collapse | ||
Limitations & tradeoffs
Safety
Bleeding at 7 days was 4.6% vs 5.0% (p=0.846), with 2 intracranial bleeds in the CDT arm vs 0.
Statistical certainty
Very few primary events (0.7% with CDT) make the effect estimate imprecise (CI 0.02–0.44).
Subgroup caution
The benefit was driven mainly by decompensation or collapse, a softer component than death or recurrence.
Design limitations
Only 7 days of follow-up are reported in the record.
Structured PICO
Does conventional catheter-directed thrombolysis reduce the composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days in patients with acute intermediate-high-risk pulmonary embolism compared to standard anticoagulation alone?
P
Population
558 patients (median age 64, 41% women) with acute intermediate-high-risk pulmonary embolism, followed for 7 days.
I
Intervention
Conventional catheter-directed thrombolysis (CDT)
C
Comparator
Standard anticoagulation alone
O
Outcome
Composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven dayscomposite
Main Result
Relative Risk: 0.1 (95% CI 0.02–0.44)
Absolute Event Rate: 0.7% vs 6.8%
p-value: p=<0.001
Catheter-directed thrombolysis significantly reduced the 7-day composite of mortality, PE recurrence, or decompensation in intermediate-high-risk pulmonary embolism compared to anticoagulation alone.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Kroupa et al. (2026) conducted an RCT in acute intermediate-high-risk pulmonary embolism (n=558). conventional catheter-directed thrombolysis vs. standard anticoagulation alone was evaluated on composite of all-cause mortality, pulmonary-embolism recurrence, or cardiorespiratory decompensation or collapse within seven days (RR 0.10, 95% CI 0.02 to 0.44, p=<0.001). Catheter-directed thrombolysis reduced mortality, PE recurrence, or decompensation compared to standard anticoagulation alone (0.7% vs 6.8%; RR 0.10; 95% CI 0.02-0.44; p<0.001).